INTRODUCTION: The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial is an adaptive platform trial testing multiple drugs to slow or prevent the progression of Alzheimer's disease in autosomal dominant Alzheimer's disease (ADAD) families. With completion of enrollment of the first two drug arms, the DIAN-TU now plans to add new drugs to the platform, designated as the Next Generation (NexGen) prevention trial. METHODS: In collaboration with ADAD families, philanthropic organizations, academic leaders, the DIAN-TU Pharma Consortium, the National Institutes of Health, and regulatory colleagues, the DIAN-TU developed innovative clinical study designs for the DIAN-TU NexGen prevention trial. RESULTS: Our expanded trial toolbox consists of a disease progression model for ADAD, primary end point DIAN-TU cognitive performance composite, biomarker development, self-administered cognitive assessments, adaptive dose adjustments, and blinded data collection through the last participant completion. CONCLUSION: These steps represent elements to improve efficacy of the adaptive platform trial and a continued effort to optimize prevention and treatment trials in ADAD.
INTRODUCTION: The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) trial is an adaptive platform trial testing multiple drugs to slow or prevent the progression of Alzheimer's disease in autosomal dominant Alzheimer's disease (ADAD) families. With completion of enrollment of the first two drug arms, the DIAN-TU now plans to add new drugs to the platform, designated as the Next Generation (NexGen) prevention trial. METHODS: In collaboration with ADAD families, philanthropic organizations, academic leaders, the DIAN-TU Pharma Consortium, the National Institutes of Health, and regulatory colleagues, the DIAN-TU developed innovative clinical study designs for the DIAN-TU NexGen prevention trial. RESULTS: Our expanded trial toolbox consists of a disease progression model for ADAD, primary end point DIAN-TU cognitive performance composite, biomarker development, self-administered cognitive assessments, adaptive dose adjustments, and blinded data collection through the last participant completion. CONCLUSION: These steps represent elements to improve efficacy of the adaptive platform trial and a continued effort to optimize prevention and treatment trials in ADAD.
Authors: Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan Journal: Lancet Neurol Date: 2013-09-04 Impact factor: 44.182
Authors: Rawan Tarawneh; Gina D'Angelo; Elizabeth Macy; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Anne M Fagan; Denise Head; Mark A Mintun; Jack H Ladenson; Jin-Moo Lee; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2011-08 Impact factor: 10.422
Authors: Hlin Kvartsberg; Flora H Duits; Martin Ingelsson; Niels Andreasen; Annika Öhrfelt; Kerstin Andersson; Gunnar Brinkmalm; Lars Lannfelt; Lennart Minthon; Oskar Hansson; Ulf Andreasson; Charlotte E Teunissen; Philip Scheltens; Wiesje M Van der Flier; Henrik Zetterberg; Erik Portelius; Kaj Blennow Journal: Alzheimers Dement Date: 2014-12-19 Impact factor: 21.566
Authors: Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Bao-Xi Qu; Qun Xiang; Liping Li; Stephen Albert Johnston; Linda S Hynan; Roger N Rosenberg Journal: J Neurol Sci Date: 2007-06-15 Impact factor: 3.181
Authors: Randall J Bateman; Paul S Aisen; Bart De Strooper; Nick C Fox; Cynthia A Lemere; John M Ringman; Stephen Salloway; Reisa A Sperling; Manfred Windisch; Chengjie Xiong Journal: Alzheimers Res Ther Date: 2011-01-06 Impact factor: 6.982
Authors: Joshua D Grill; Randall J Bateman; Virginia Buckles; Angela Oliver; John C Morris; Colin L Masters; William E Klunk; John M Ringman Journal: Alzheimers Res Ther Date: 2015-07-22 Impact factor: 6.982
Authors: Henrik Zetterberg; David Wilson; Ulf Andreasson; Lennart Minthon; Kaj Blennow; Jeffrey Randall; Oskar Hansson Journal: Alzheimers Res Ther Date: 2013-03-28 Impact factor: 6.982
Authors: Eric McDade; Guoqiao Wang; Brian A Gordon; Jason Hassenstab; Tammie L S Benzinger; Virginia Buckles; Anne M Fagan; David M Holtzman; Nigel J Cairns; Alison M Goate; Daniel S Marcus; John C Morris; Katrina Paumier; Chengjie Xiong; Ricardo Allegri; Sarah B Berman; William Klunk; James Noble; John Ringman; Bernardino Ghetti; Martin Farlow; Reisa A Sperling; Jasmeer Chhatwal; Stephen Salloway; Neill R Graff-Radford; Peter R Schofield; Colin Masters; Martin N Rossor; Nick C Fox; Johannes Levin; Mathias Jucker; Randall J Bateman Journal: Neurology Date: 2018-09-14 Impact factor: 9.910
Authors: Aaron P Schultz; Reina W Kloet; Hamid R Sohrabi; Louise van der Weerd; Sanneke van Rooden; Marieke J H Wermer; Laure Grand Moursel; Maqsood Yaqub; Bart N M van Berckel; Pratishtha Chatterjee; Samantha L Gardener; Kevin Taddei; Anne M Fagan; Tammie L Benzinger; John C Morris; Reisa Sperling; Keith Johnson; Randall J Bateman; M Edip Gurol; Mark A van Buchem; Ralph Martins; Jasmeer P Chhatwal; Steven M Greenberg Journal: Ann Neurol Date: 2019-08-12 Impact factor: 10.422
Authors: Guoqiao Wang; Dean Coble; Eric M McDade; Jason Hassenstab; Anne M Fagan; Tammie L S Benzinger; Randall J Bateman; John C Morris; Chengjie Xiong Journal: Alzheimers Dement Date: 2019-02-15 Impact factor: 21.566
Authors: Kirsi M Kinnunen; David M Cash; Teresa Poole; Chris Frost; Tammie L S Benzinger; R Laila Ahsan; Kelvin K Leung; M Jorge Cardoso; Marc Modat; Ian B Malone; John C Morris; Randall J Bateman; Daniel S Marcus; Alison Goate; Stephen P Salloway; Stephen Correia; Reisa A Sperling; Jasmeer P Chhatwal; Richard P Mayeux; Adam M Brickman; Ralph N Martins; Martin R Farlow; Bernardino Ghetti; Andrew J Saykin; Clifford R Jack; Peter R Schofield; Eric McDade; Michael W Weiner; John M Ringman; Paul M Thompson; Colin L Masters; Christopher C Rowe; Martin N Rossor; Sebastien Ourselin; Nick C Fox Journal: Alzheimers Dement Date: 2017-07-22 Impact factor: 21.566
Authors: Diego Castillo-Barnes; Li Su; Javier Ramírez; Diego Salas-Gonzalez; Francisco J Martinez-Murcia; Ignacio A Illan; Fermin Segovia; Andres Ortiz; Carlos Cruchaga; Martin R Farlow; Chengjie Xiong; Neil R Graff-Radford; Peter R Schofield; Colin L Masters; Stephen Salloway; Mathias Jucker; Hiroshi Mori; Johannes Levin; Juan M Gorriz Journal: Inf Fusion Date: 2020-01-07 Impact factor: 12.975
Authors: Roderick A Corriveau; Walter J Koroshetz; Jordan T Gladman; Sophia Jeon; Debra Babcock; David A Bennett; S Thomas Carmichael; Susan L-J Dickinson; Dennis W Dickson; Marian Emr; Howard Fillit; Steven M Greenberg; Michael L Hutton; David S Knopman; Jennifer J Manly; Karen S Marder; Claudia S Moy; Creighton H Phelps; Paul A Scott; William W Seeley; Beth-Anne Sieber; Nina B Silverberg; Margaret L Sutherland; Angela Taylor; Christine L Torborg; Salina P Waddy; Amelie K Gubitz; David M Holtzman Journal: Neurology Date: 2017-11-08 Impact factor: 9.910